Antonio Hardan, MD
Psychiatry · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hardan’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence C52121 · Current
Licensed to practise in California · since 2005 · expires 2027-03-31 · St Joseph'S University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$2,921
Medicare paid this office $2,921 for 11 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
11 Original Medicare patients in 2024. Average age 34 · Under 65 100% · 85 and older 0% · Health risk score 0.69. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
The office billed $14,896, Medicare allowed $4,868 and paid $2,921; for 40 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 11 | 40 | 34 | 0.69 | $14,896 | $2,921 |
| 2020 | 12 | 42 | 46 | 1.57 | $12,397 | $2,293 |
| 2017 | 41 | 103 | 61 | 1.51 | $23,963 | $5,908 |
| 2016 | 56 | 150 | 61 | 1.76 | $35,703 | $9,394 |
| 2015 | 61 | 161 | 60 | 1.69 | $35,372 | $9,397 |
| 2014 | 39 | 133 | 57 | 1.26 | $25,954 | $8,177 |
| 2013 | 61 | 163 | 54 | 1.29 | $32,499 | $8,606 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2017: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $4,399 | $63 |
2016: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $7,120 | $63 |
2015: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 53 | $7,883 | $64 |
2014: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $6,789 | $64 |
2013: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $7,761 | $62 |
Drugs they prescribed that Part D paid
$41,022
Pharmacies billed $41,022 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 314) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
295 generic and 19 brand-name prescriptions · $41,022 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rexulti | 11 | $27,684 | $2,517 |
| Guanfacine | 18 | $1,203 | $67 |
| Divalproex Sodium Er | 14 | $987 | $70 |
| Fluvoxamine Maleate | 26 | $932 | $36 |
| Risperidone | 41 | $606 | $15 |
See all 13 drugs
| Rexulti | 11 | $27,684 | $2,517 |
| Guanfacine | 18 | $1,203 | $67 |
| Divalproex Sodium Er | 14 | $987 | $70 |
| Fluvoxamine Maleate | 26 | $932 | $36 |
| Risperidone | 41 | $606 | $15 |
| Olanzapine Odt | 12 | $494 | $41 |
| Clonazepam | 38 | $378 | $10 |
| Trazodone | 29 | $370 | $13 |
| Aripiprazole | 31 | $319 | $10 |
| Fluoxetine | 22 | $176 | $8 |
| Benztropine Mesylate | 14 | $152 | $11 |
| Topiramate | 26 | $105 | $4 |
| Escitalopram | 12 | $27 | $2 |
Year by year
| 2024 | 314 | None | 0% (0) | 6% | $41,022 |
| 2023 | 227 | None | 0% (0) | 16% | $58,591 |
| 2022 | 148 | None | 0% (0) | 25% | $47,547 |
| 2021 | 139 | None | 0% (0) | 35% | $67,910 |
| 2020 | 143 | None | 0% (0) | 33% | $57,869 |
| 2019 | 111 | None | 0% (0) | 31% | $37,104 |
| 2018 | 43 | None | 0% (0) | None | $13,948 |
| 2017 | 108 | None | 0% (0) | None | $22,595 |
| 2016 | 127 | None | 0% (0) | 9% | $19,318 |
| 2015 | 89 | None | 0% (0) | 24% | $23,517 |
| 2014 | 46 | None | 0% (0) | None | $5,699 |
| 2013 | 33 | None | 0% (0) | None | $8,885 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Rexulti | 13 | $29,748 | $2,288 |
| Abilify | 23 | $18,198 | $791 |
| Fluvoxamine Maleate | 20 | $882 | $44 |
| Guanfacine | 12 | $793 | $66 |
| Divalproex Sodium Er | 13 | $592 | $46 |
| Trazodone | 30 | $363 | $12 |
| Topiramate | 25 | $355 | $14 |
| Risperidone | 26 | $276 | $11 |
| Benztropine Mesylate | 12 | $188 | $16 |
| Aripiprazole | 17 | $167 | $10 |
| Clonazepam | 26 | $165 | $6 |
2022: 7 drugs
| Rexulti | 11 | $23,747 | $2,159 |
| Abilify | 16 | $12,300 | $769 |
| Chlorpromazine | 12 | $9,069 | $756 |
| Fluvoxamine Maleate | 18 | $1,059 | $59 |
| Topiramate | 23 | $219 | $10 |
| Risperidone | 17 | $132 | $8 |
| Aripiprazole | 12 | $128 | $11 |
2021: 8 drugs
| Abilify | 25 | $27,587 | $1,103 |
| Rexulti | 11 | $21,721 | $1,975 |
| Chlorpromazine | 14 | $15,401 | $1,100 |
| Divalproex Sodium Er | 12 | $1,812 | $151 |
| Fluvoxamine Maleate | 13 | $608 | $47 |
| Topiramate | 13 | $176 | $14 |
| Risperidone | 17 | $167 | $10 |
| Trazodone | 12 | $136 | $11 |
2020: 6 drugs
| Abilify | 29 | $32,051 | $1,105 |
| Divalproex Sodium Er | 24 | $512 | $21 |
| Aripiprazole | 11 | $351 | $32 |
| Risperidone | 21 | $308 | $15 |
| Duloxetine | 11 | $105 | $10 |
| Topiramate | 12 | $53 | $4 |
2019: 4 drugs
| Abilify | 25 | $26,577 | $1,063 |
| Aripiprazole | 12 | $511 | $43 |
| Divalproex Sodium Er | 20 | $305 | $15 |
| Risperidone | 20 | $132 | $7 |
2018: 1 drug
| Chlorpromazine | 12 | $11,107 | $926 |
2017: 5 drugs
| Chlorpromazine | 11 | $13,914 | $1,265 |
| Aripiprazole | 14 | $1,919 | $137 |
| Escitalopram | 18 | $193 | $11 |
| Venlafaxine Hcl Er | 18 | $136 | $8 |
| Trazodone | 16 | $68 | $4 |
2016: 5 drugs
| Aripiprazole | 35 | $12,295 | $351 |
| Venlafaxine Hcl Er | 24 | $193 | $8 |
| Escitalopram | 24 | $152 | $6 |
| Benztropine Mesylate | 13 | $109 | $8 |
| Trazodone | 12 | $42 | $4 |
2015: 3 drugs
| Abilify | 17 | $15,545 | $914 |
| Escitalopram | 28 | $419 | $15 |
| Sertraline | 14 | $72 | $5 |
2014: 1 drug
| Escitalopram | 33 | $2,600 | $79 |
2013: 1 drug
| Escitalopram | 26 | $4,536 | $174 |
Money from drug and device companies
$1,590 in 2024
| 2024 | 1 | 1 | $1,590 | $1,590 |
| 2020 | 1 | 2 | $1,868 | $1,868 |
| 2019 | 2 | 2 | None | $217 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| F. Hoffmann-La Roche AG | None | $1,590 | 1 payment
|
See the published payment
| F. Hoffmann-La Roche AG | Consulting · 2024-08-08 | None | $1,590 |
See earlier years (2020, 2019)
2020: $1,868
| Roche Products | Non-Covered Product | $1,868 | 2 payments
|
2019: $217
| Allergan | Vraylar | $124 | 1 payment
|
| Genentech | None | $93 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · An Observational Longitudinal Study in Offspring of Parents With Bipolar Disorder To Evaluate the Relationship of Impairment in Psychosocial Functioning With the Manifestation of Mood Symptoms Over 24 Months · 2022 | Their institution | $100,720 |
| Hoffmann-La Roche Limited · Study To Assess Scales for Rrb in Asd Non Drug Study Digital Biomarker · 2020 | Their institution | $30,729 |
| Janssen Research & Development, LLC · An Observational Longitudinal Study in Offspring of Parents With Bipolar Disorder To Evaluate the Relationship of Impairment in Psychosocial Functioning With the Manifestation of Mood Symptoms Over 24 Months · 2021 | Their institution | $13,545 |
| Genentech, Inc. · Study To Assess Scales for Rrb in Asd Non Drug Study Digital Biomarker · 2019 | Their institution | $8,419 |
| Hoffmann-La Roche Limited · Study To Assess Scales for Rrb in Asd Non Drug Study Digital Biomarker · 2021 | Their institution | $3,077 |
Professional record
- NPI
- 1407829286
- Licence
- CA C52121, PA MD051151LCalifornia C52121: Current · expires 2027-03-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084P0804X (2084P0804X); Federal specialty code 174400000X (174400000X); Psychiatry (2084P0800X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-02-10
- NPI last updated
- 2024-04-30
- NPI record certified
- 2024-04-30
This is when the NPI record was last certified, not a medical board exam.